Clinical Study Support by Long-Term Stability Studies of Alpha₁-Proteinase Inhibitor and Urea in Relevant Biological...

Area of Science:

• Clinical chemistry
• Bioanalytical method validation
• Protein stability studies

Background:

• Regulatory guidelines emphasize the need for analyte stability data in clinical studies.
• Human alpha1-proteinase inhibitor (A1PI) and urea are key analytes in clinical A1PI research.
• Understanding analyte stability is crucial for accurate bioanalytical method validation.

Purpose of the Study:

• To assess the stability of human alpha1-proteinase inhibitor (A1PI) protein and activity, and urea.
• To evaluate analyte stability in citrated human plasma and bronchoalveolar lavage (BAL)-mimicking matrices.
• To provide stability data supporting bioanalytical method validation for A1PI studies.

Main Methods:

• Prepared stability samples in plasma and BAL-mimicking matrices.
• Stored samples at -20 °C and -60 °C for up to 24 months.
• Measured A1PI protein (nephelometry, ELISA), A1PI activity (immunosorbent assay), and urea (enzymatic assay).

Main Results:

• A1PI protein and activity met stability criteria (100 ± 20%) in both matrices at tested temperatures.
• Urea remained stable in both matrices at -20 °C for 18 months.
• Plasma samples exhibited better stability than BAL-mimicking samples; activity loss was greater than protein loss.

Conclusions:

• Human A1PI and urea demonstrate adequate stability in citrated plasma and BAL-mimicking samples.
• Stability is confirmed for at least 15 months, supporting their use in clinical studies.
• Data supports the reliability of bioanalytical methods for these analytes under specified storage conditions.